Overview An Acute Migraine Factorial Study Status: COMPLETED Trial end date: 2018-02-08 Target enrollment: Participant gender: Summary The study consists of a screening visit, out-patient treatment of a moderate or severe migraine attack with a single dose of the study medication within 8 weeks, and End-of-Study Visit 2-7 days after dosing.Phase: PHASE2 Details Lead Sponsor: Allodynic Therapeutics, IncTreatments: AcetaminophenNaltrexone